Kalaris Therapeutics, Inc.

KLRSSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1754068

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$165.0K
Research and Development Expense	$133.1M	$118.9M	$120.7M	$49.7M	$16.2M
Operating Expenses	$199.9M	$171.2M	$169.8M	$71.3M	$26.9M
Operating Income (Loss)	-$199.9M	-$171.2M	-$169.8M	-$71.3M	-$26.7M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$190.5M	-$169.0M	-$171.0M	-$69.8M	—
Income Tax Expense (Benefit)	-$126.0K	-$265.0K	$1.0M	$1.0M	—
Net Income (Loss) Attributable to Parent	-$190.4M	-$168.7M	-$172.0M	-$69.8M	-$23.8M
Earnings Per Share, Basic	-$42.09	-$2.20	-$2.74	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$190.8M	$277.1M	$286.6M	$370.8M	$139.4M
Assets, Current	$187.6M	$243.1M	$253.3M	$361.3M	$127.3M
Cash and Cash Equivalents, at Carrying Value	$90.1M	$106.1M	$201.7M	$122.7M	$61.1M
Liabilities	$45.0M	$52.6M	$61.3M	$17.8M	$17.8M
Liabilities, Current	$28.4M	$24.3M	$37.9M	$12.3M	$9.1M
Accounts Payable, Current	$6.8M	$3.0M	$8.4M	$963.0K	$630.0K
Stockholders' Equity Attributable to Parent	$224.5M	$225.3M	$353.1M	-$51.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$124.5M	-$142.1M	-$106.3M	-$60.8M	-$20.2M
Net Cash Provided by (Used in) Investing Activities	$38.0M	-$80.5M	$186.0M	-$169.5M	-$64.6M
Net Cash Provided by (Used in) Financing Activities	$70.5M	$127.0M	$232.0K	$292.0M	$120.9M
Payments to Acquire Property, Plant, and Equipment	—	—	$26.0K	$235.0K	$339.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)